Brokerages Set BioLife Solutions, Inc. (NASDAQ:BLFS) Target Price at $31.29

BioLife Solutions, Inc. (NASDAQ:BLFS) has been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $31.2857.

BLFS has been the subject of a number of analyst reports. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Stephens initiated coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th.

Insider Activity

In other news, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $28.55, for a total value of $21,412,500.00. Following the completion of the transaction, the insider owned 5,957,165 shares of the company’s stock, valued at $170,077,060.75. The trade was a 11.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $25.53, for a total transaction of $255,300.00. Following the completion of the transaction, the chief marketing officer directly owned 124,618 shares of the company’s stock, valued at $3,181,497.54. This trade represents a 7.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,768,281 shares of company stock valued at $45,387,484 in the last quarter. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in BLFS. Ameritas Investment Partners Inc. lifted its position in BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in BioLife Solutions by 2.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after buying an additional 500 shares in the last quarter. Isthmus Partners LLC lifted its position in BioLife Solutions by 0.4% during the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock worth $2,846,000 after buying an additional 509 shares in the last quarter. Sei Investments Co. lifted its position in BioLife Solutions by 0.5% during the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after buying an additional 547 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in BioLife Solutions by 2.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after buying an additional 555 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $27.54 on Monday. The firm has a market cap of $1.32 billion, a P/E ratio of -229.48 and a beta of 1.95. The firm has a 50 day simple moving average of $25.95 and a 200 day simple moving average of $23.57. BioLife Solutions has a fifty-two week low of $19.10 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The business had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that BioLife Solutions will post -0.3 EPS for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.